News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GBI Research Release: Systemic Psoriasis Therapeutics: Increased Disease Awareness And Promising Novel Drugs To Drive Market Growth By 2020

2/4/2014 11:24:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK (GBI Research), 4 February 2014 -- The systemic psoriasis treatment market value in the eight major countries (8MM) — the US, Canada, France, Germany, Italy, Spain, the UK and Japan — is expected to more than double in the near future, jumping from $5 billion in 2013 to $10.4 billion by 2020, at a significant Compound Annual Growth Rate (CAGR) of 11.1%, forecasts business intelligence provider GBI Research.

The company’s new report* states that across the 8MM, 4.1 million people were diagnosed with some form of moderate-to-severe psoriasis in 2013. This number is expected to climb slightly to 4.4 million by 2020, with 1.5 million of the population being treated with systemic agents.

Fiona Chisholm, Analyst for GBI Research, says: “This growth in the treatment population will be driven by a marginal rise in the global prevalence of psoriasis, as well as an increase in the diagnosis rate resulting from higher disease awareness and improved diagnostic methods.

“Additionally, psoriasis is increasingly being recognized as a serious systemic disease with associated quality of life impairment and disability, rather than as a simply cutaneous disease. As perceptions of psoriasis continue to change, healthcare professionals will consider treatment as non-optional.”

Although some revenue losses are anticipated to occur throughout the forecast period, due to patent expiries, the introduction of new, novel biologics with positive efficacy profiles will drive further market growth.

According to GBI Research, secukinumab, brodalumab and ixekizumab are three particularly promising, late-stage pipeline monoclonal antibodies directly targeting IL–17, a pro-inflammatory cytokine. In addition to these upcoming biologics, some orally administered, small molecule compounds are also expected to enter the market over the coming years, such as Xeljanz, a janus kinase inhibitor, and apremilast, a PDE4 inhibitor.

“These pipeline molecules have demonstrated very strong efficacy and safety profiles, which are largely superior to those of the currently marketed products,” Chisholm concludes.

*Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

This report provides an analysis of the pipeline for psoriasis, including a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.


GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus